Skip Navigation


JAC Advance Access originally published online on April 21, 2005
Journal of Antimicrobial Chemotherapy 2005 55(6):817-820; doi:10.1093/jac/dki127
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
55/6/817    most recent
dki127v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (4)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Shafer, R. W.
Right arrow Articles by Schapiro, J. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Shafer, R. W.
Right arrow Articles by Schapiro, J. M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2005. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions{at}oupjournals.org

Leading article

Drug resistance and antiretroviral drug development

Robert W. Shafer1,* and Jonathan M. Schapiro1,2

1 Division of Infectious Diseases, Department of Medicine, Stanford University, Stanford, CA 94305, USA; 2 National Hemophilia Center, Sheba Medical Center, Tel Aviv, Israel

* Corresponding author. Email: rshafer{at}stanford.edu

As more drugs for treating HIV have become available, drug resistance profiles within antiretroviral drug classes have become increasingly important for researchers developing new drugs and for clinicians integrating new drugs into their clinical practice. In vitro passage experiments and comprehensive phenotypic susceptibility testing are used for the pre-clinical evaluation of drug resistance. Clinical studies are required, however, to delineate the full spectrum of mutations responsible for resistance to a new drug and to identify the settings in which a new drug is likely to be most useful for salvage therapy.

Keywords: HIV , profiles , antivirals , clinical studies , genotype , phenotype


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Antimicrob. Agents Chemother.Home page
S. Abdurahman, A. Vegvari, M. Youssefi, M. Levi, S. Hoglund, E. Andersson, P. Horal, B. Svennerholm, J. Balzarini, and A. Vahlne
Activity of the Small Modified Amino Acid {alpha}-Hydroxy Glycineamide on In Vitro and In Vivo Human Immunodeficiency Virus Type 1 Capsid Assembly and Infectivity
Antimicrob. Agents Chemother., October 1, 2008; 52(10): 3737 - 3744.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
K. A. Delviks-Frankenberry, G. N. Nikolenko, R. Barr, and V. K. Pathak
Mutations in Human Immunodeficiency Virus Type 1 RNase H Primer Grip Enhance 3'-Azido-3'-Deoxythymidine Resistance
J. Virol., July 1, 2007; 81(13): 6837 - 6845.
[Abstract] [Full Text] [PDF]

Home page
 BiostatisticsHome page
N. Beerenwinkel and M. Drton
A mutagenetic tree hidden Markov model for longitudinal clonal HIV sequence data
Biostat., January 1, 2007; 8(1): 53 - 71.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.